Inarigivir soproxil

Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant HCV variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems. Inarigivir soproxil, an orally bioavailable proagent of SB 9000, has broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, respiratory syncytial virus and influenza and HBV[1][2].

Product Specifications

CAS Number

[942123-43-5]

Product Name Alternative

SB9200; GS-9992

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HBV; HCV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Inarigivir_soproxil.html

Purity

99.87

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CO[C@H]1[C@H](N(C=CC2=O)C(N2)=O)O[C@H](CO)[C@H]1OP(OC[C@H]3O[C@@H](N4C5=NC=NC(N)=C5N=C4)C[C@@H]3O)(SCOC(OC(C)C)=O)=O

Molecular Formula

C25H34N7O13PS

Molecular Weight

703.62

Precautions

H302, H315, H319, H335

References & Citations

[1]Meleri Jones, et al. SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. J Med Virol. 2017 Sep;89 (9) :1620-1628.|[2]Manasa Suresh, et al. Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks. PLoS One. 2017 Jan 5;12 (1) :e0169631.